Xcellerant Ventures
  • Portfolio
  • Team
  • About
  • Invest
  • News
  • Contact
Select Page
CRISPR QC Launches Three Innovative Products and Unveils Revamped Website

CRISPR QC Launches Three Innovative Products and Unveils Revamped Website

by Xcellerant Ventures | Aug 12, 2024 | Portfolio Company News

Origionally posted on EIN Presswire: https://www.einpresswire.com/article/710284206/lenoss-medical-oversubscribes-4-million-series-a-financing   SAN DIEGO–(BUSINESS WIRE)–CRISPR QC, a pioneering biotechnology company in San Diego, is excited to...
In vitro CRISPR-Cas Cleavage Assays Streamline Gene Editing Workflows

In vitro CRISPR-Cas Cleavage Assays Streamline Gene Editing Workflows

by Xcellerant Ventures | Jul 27, 2024 | Portfolio Company News

Origionally posted on CRISPR QC’s website: https://crisprqc.com/wp-content/uploads/2024/08/20240806-CRISPR-Cleave-Case-Study-Layout.pdf   Key Takeaways: CRISPR QC’s in vitro CRISPR-Cas cleavage assays can streamline CRISPR workflows by identifying optimal...
Optimizing Ribonucleoprotein (RNP) Complexes and Improving Multiplex Gene Editing Efficiency with Data-Driven gRNA Selection

Optimizing Ribonucleoprotein (RNP) Complexes and Improving Multiplex Gene Editing Efficiency with Data-Driven gRNA Selection

by Xcellerant Ventures | Jul 26, 2024 | Portfolio Company News

Origionally posted on CRISPR QC’s website: https://crisprqc.com/wp-content/uploads/2024/08/20240806-CRISPR-RNP-Case-Study-Layout.pdf   Key Takeaways: A critical gap exists in the CRISPR workflow: the lack of an in vitro QC step. The CRISPR Analytics...
Accelerating CRISPR-Cas Optimization with Quantitative DNA Binding Analysis

Accelerating CRISPR-Cas Optimization with Quantitative DNA Binding Analysis

by Xcellerant Ventures | Jul 25, 2024 | Portfolio Company News

Origionally posted on CRISPR QC’s website: https://crisprqc.com/wp-content/uploads/2024/08/20240806-CRISPR-DNA-Case-Study-Layout.pdf   Key Takeaways: The CRISPR Analytics Platform is an in vitro tool for measuring CRISPR editing efficiency, as well as, RNP...
Unlocking the Power of CRISPR Technology for Drug Development with Ross Bundy CRISPR QC

Unlocking the Power of CRISPR Technology for Drug Development with Ross Bundy CRISPR QC

by Xcellerant Ventures | Jun 11, 2024 | Portfolio Company News

Origionally posted on Empowered Patient Podcast: https://empoweredpatientradio.com/unlocking-the-power-of-crispr-technology-for-drug-development-with-ross-bundy-crispr-qc   Ross Bundy, President and CEO of CRISPR QC, shines a light on the current state of CRISPR...
« Older Entries

Recent Posts

  • TruLite Health Partners with Lee Health to Elevate Health Equity Strategy
  • TruLite Health Selected for Microsoft Pegasus Program
  • Xcellerant Ventures Leads DeepLook Medical’s Series A Round
  • DeepLook Medical’s DL Precise™ improved the performance of the breast imaging department with 12% favorable change in recall rates
  • Feasibility Study Evaluates Potential of Digital Health Platform to Help Patients Manage Prostate Cancer Symptoms

Recent Comments

No comments to show.
  • Portfolio
  • Team
  • About
  • Invest
  • News
  • Contact
  • Privacy Policy
© Xcellerant Ventures 2023